Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) EBIT Margin: 2023-2025

Historic EBIT Margin for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -15,845.69%.

  • NewAmsterdam Pharma Co N.V's EBIT Margin fell 1575980.00% to -15,845.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -575.81%, marking a year-over-year decrease of 2769.00%. This contributed to the annual value of -386.91% for FY2024, which is 91165.00% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's EBIT Margin is -15,845.69%, which was down 8,413.14% from -186.13% recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's EBIT Margin peaked at -85.89% during Q3 2024, and registered a low of -15,845.69% during Q3 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median EBIT Margin value was -2,306.93% (recorded in 2024), while the average stood at -3,274.48%.
  • Per our database at Business Quant, NewAmsterdam Pharma Co N.V's EBIT Margin soared by 602,193bps in 2024 and then slumped by 1,575,980bps in 2025.
  • NewAmsterdam Pharma Co N.V's EBIT Margin (Quarterly) stood at -6,360.40% in 2023, then spiked by 602,193bps to -338.47% in 2024, then plummeted by 1,575,980bps to -15,845.69% in 2025.
  • Its EBIT Margin was -15,845.69% in Q3 2025, compared to -186.13% in Q2 2025 and -2,314.47% in Q1 2025.